Ascletis Pharma Inc.
Ascletis Pharma Inc. (ASCLF) Revenue
Annual & quarterly revenue history · segment & region breakdown
ASCLF · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsAscletis Pharma Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 53.99% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2016 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.00B | +$0.00B | +53.99% |
| 2024-12-31 | $0.00B | -$0.06B | -97.73% |
| 2023-12-31 | $0.06B | +$0.00B | +4.63% |
| 2022-12-31 | $0.05B | -$0.02B | -29.64% |
| 2021-12-31 | $0.08B | +$0.04B | +119.64% |
| 2020-12-31 | $0.04B | -$0.14B | -79.82% |
| 2019-12-31 | $0.17B | +$0.01B | +4.28% |
| 2018-12-31 | $0.17B | +$0.11B | +212.63% |
| 2017-12-31 | $0.05B | +$0.02B | +61.34% |
| 2016-12-31 | $0.03B | — | — |
Compare revenue vs peers
BiotechnologyCompare ASCLF revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Ascletis Pharma Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Ascletis Pharma Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in CNY.
Data sourced from Ascletis Pharma Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
ASCLF revenue · 4 questionsASCLF's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 53.99% year-over-year from $0.00B in FY2025.
▸ Source: FMP · Ascletis Pharma Inc. SEC filings · GAAP · Ascletis Pharma Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026